The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.
The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.
New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.
Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy.
In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment.1
After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities.
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.
NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.
A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.
If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.
